Andrew Left's Conviction Could Change The Rules For Every Market Commentator...But How?

Pfizer said the U.S. FDA approved an expanded indication for Hympavzi on June 8, 2026, extending use to hemophilia A or B patients aged 12+ with inhibitors and pediatric patients with or without inhibitors, and adding routine prophylaxis for certain adults and children 6+. On June 7, Pfizer presented Phase 2b results for berobenatide. On May 31, it reported Breakwater Phase 3 Cohort 3 data, with median progression-free survival nearly doubled for BRAFTOVI vs comparator.

Anthropic said the U.S. Commerce Department ordered it to suspend foreign access to its Fable 5 and Mythos 5 AI models “whether inside or outside the United States,” citing national security concerns. Anthropic disabled access to both models for all customers to comply, after the government found potential “jailbreak” vulnerabilities. The move could affect frontier AI export controls and investor sentiment.

Sen. Elizabeth Warren urged the SEC to delay SpaceX’s planned IPO, citing “inaccurate or misleading” valuation/accounting, governance concerns, and potential index-fund/index-provider risks. In a letter to SEC Chair Paul Atkins, she said trading was expected to start Friday. Reuters reported SpaceX targets a ~$1.75 trillion valuation and raises ~$75 billion; it reported $18.67B revenue and a $4.94B 2025 net loss.

Iran reportedly declared Elon Musk-linked assets, including Starlink infrastructure, legitimate military targets, citing alleged US actions. Microsoft’s Xbox is preparing a major restructuring under CEO Asha Sharma, with layoffs and reduced marketing/operations spending. xAI faces a lawsuit over Grok safety concerns. The EU ordered Meta to share WhatsApp access with rivals amid antitrust scrutiny. Kalshi added integrity safeguards; New York requires disclosure of AI-generated actors in ads.

Belite Bio (NASDAQ: BLTE) said it has completed the rolling submission of its New Drug Application to the FDA for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1). The NDA began in April 2026 under Breakthrough Therapy Designation. After the 60-day FDA review, a PDUFA target action date would be set, according to the company.

Sanofi said the FDA granted accelerated approval for Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin in children ages 8–17 with recently diagnosed stage 3 type 1 diabetes, based on the PROTECT phase 3 study and data from a program treating 900+ patients. The label is not for non-autoimmune dysglycemia. Common adverse events include lymphopenia and rash; serious risks include cytokine release syndrome and viral reactivation. Accelerated approval depends on confirmatory benefit